Phase I/II Study of hLL1-DOX in Relapsed NHL and CLL
Status:
Terminated
Trial end date:
2017-10-01
Target enrollment:
Participant gender:
Summary
The primary objectives are to evaluate the safety and tolerability of hLL1-DOX, and to
determine the maximum tolerated dose (MTD) regimen (in terms of a dose and its associated
dosing schedule). The secondary objectives are to obtain information on efficacy,
pharmacodynamics, pharmacokinetics, and immunogenicity, and to determine the optimal dose for
subsequent studies.